Navigation Links
Amgen Announces Webcast of 2009 Third Quarter Financial Results
Date:10/15/2009

THOUSAND OAKS, Calif., Oct. 15 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that it plans to report its third quarter financial results on Wednesday, Oct. 21, 2009 after the close of the financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. Pacific Time. Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen's senior management team.

Live audio of the conference call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public. The conference call, including the question and answer session, is expected to last approximately one hour.

The webcast of the conference, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's Web site, www.amgen.com, under Investors. Information regarding presentation times, webcast availability, and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay 72 hours after the event.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

    CONTACT: Amgen, Thousand Oaks
    David Polk, 805-447-4613 (media)
    Arvind Sood, 805-447-1060 (investors)

(Logo: http://www.newscom.com/cgi-bin/prnh/20081015/AMGENLOGO)

SOURCE Amgen


'/>"/>
SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference
2. Amgen to Present at the Morgan Stanley Global Healthcare Unplugged Conference
3. Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
4. Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August
5. Amgen Exercises Option for Exclusive License to Cytokinetics Cardiac Contractility Program That Includes CK-1827452
6. Amgen Announces Voting Results Of Annual Meeting Of Stockholders
7. Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
8. Preclinical Data From Amgens Oncology Pipeline to be Presented at AACR
9. Amgen to Present at the Cowen and Company Annual Healthcare Conference
10. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
11. Amgens Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... , ... Executive search firm, Slone Partners, announces the placement ... a distinguished life sciences expert with a proven track record in strategic global ... range of services related to laboratory testing and analysis for the pharmaceutical, medical ...
(Date:3/27/2017)... Infectex Ltd., a Russian portfolio company of Maxwell Biotech Venture Fund (MBVF), today ... standard drug therapy regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). SQ109 is a ... ) and the US National Institutes of Health. Continue ... ... ...
(Date:3/27/2017)... ... March 27, 2017 , ... A research team led by ... in JoVE’s Video Journal, the world’s first peer-reviewed scientific video journal. The article ... coronary artery disease (CAD). Lam is an assistant professor at the Department of ...
(Date:3/24/2017)... and ROCKVILLE, Md. , March ... of Maxwell Biotech Venture Fund (MBVF), today announced positive ... added to the standard drug therapy regimen in patients ... small molecule drug discovered by scientists at Sequella, Inc. ... Institutes of Health. A total of ...
Breaking Biology Technology:
(Date:2/26/2017)... , Feb. 25, 2017  Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... Recidivism and Reentry. "Too often, too ... prisons and county jails are trying to tackle ... inmates and friends and family members. While significant steps ...
(Date:2/21/2017)... 21, 2017 Der weltweite Biobanking-Sektor ... Nach einem Gespräch mit mehr als 50 Vertretern aus verschiedenen ... überwinden gilt, um diese Prognose zu realisieren. ... Zu ... der finanziellen Mittel für die Biobank, die Implementierung Zeit ...
(Date:2/13/2017)... , Feb. 13, 2017 Former 9/11 Commission ... Judiciary Committee, Janice Kephart of Identity Strategy ... Donald Trump,s "Executive Order: Protecting the Nation ... 27, 2017):  "As President Trump,s ,Travel Ban, ... has now essentially banned the travel ban, it is ...
Breaking Biology News(10 mins):